Price Chart

Profile

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
URL https://www.sanofi.com
Investor Relations URL https://www.sanofi.com/en/investors
HQ State/Province N/A
Sector Health Care
Industry Pharmaceuticals
Equity Style Large Cap/Blend
Next Earnings Release Jan. 31, 2025 (est.)
Last Earnings Release Oct. 25, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date May. 09, 2024

Profile

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
URL https://www.sanofi.com
Investor Relations URL https://www.sanofi.com/en/investors
HQ State/Province N/A
Sector Health Care
Industry Pharmaceuticals
Equity Style Large Cap/Blend
Next Earnings Release Jan. 31, 2025 (est.)
Last Earnings Release Oct. 25, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date May. 09, 2024